401519-96-8
|
|
|
- CAS号:
- 401519-96-8
- 英文名:
- NCX 1000
- 英文别名:
- NCX 1000;Cholan-24-oic acid, 3,7-dihydroxy-, 2-methoxy-4-[(1E)-3-[4-(nitrooxy)butoxy]-3-oxo-1-propen-1-yl]phenyl ester, (3α,5β,7β)-
- 中文名:
- 401519-96-8
- 中文别名:
- 化合物 T19471;化合物 NCX 1000
- CBNumber:
- CB43175558
- 分子式:
- C38H55NO10
- 分子量:
- 685.86
- MOL File:
- 401519-96-8.mol
|
|
|
401519-96-8化学性质
-
沸点:
-
758.3±60.0 °C(Predicted)
-
|
-
密度:
-
1.198±0.06 g/cm3(Predicted)
-
|
-
储存条件:
-
Store at -20°C
-
|
-
溶解度:
-
Soluble in DMSO
-
|
-
形态:
-
Solid
-
|
-
酸度系数(pKa):
-
14.79±0.70(Predicted)
-
|
-
颜色:
-
White to off-white
-
|
401519-96-8性质、用途与生产工艺
NCX 1000 是一种肝特异性 NO 供体，它来源于熊去氧胆酸。
|
Human Endogenous Metabolite
|
NCX-1000 (15 mg/kg, p.o.) prevents ascite formation, reduces collagen deposition in CCl4-treated rats. NCX-1000 administration almost completely reverts portal hypertension induced by CCl4, and reduces portal pressure in cirrhotic rats. NCX-1000 reverts HSC contraction induced by FCS, and also inhibits MCP-1 release from HSCs stimulated with TNF-α and IFN-γ. NCX-1000 (28 mg/kg, p.o.) decreases portal pressure without affecting mean arterial pressure and heart rate in rats. NCX-1000 also reduces vasoconstriction by 60% caused by 30 μM NE in rats. Administration of NCX-1000 to BDL and sham operated rats results in a similar increase of nitrite/nitrate and cGMP concentrations in the liver.
401519-96-8
上下游产品信息
上游原料
下游产品
| 更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
|---|
| 2024/08/19 | HY-U00023 | 401519-96-8
NCX 1000 | 401519-96-8 | 1 mg | 2906元 |
401519-96-8, 401519-96-8 相关搜索:
- 抑制剂
- C38H55NO10
- 化合物 NCX 1000
- 化合物 T19471
- 401519-96-8
- Cholan-24-oic acid, 3,7-dihydroxy-, 2-methoxy-4-[(1E)-3-[4-(nitrooxy)butoxy]-3-oxo-1-propen-1-yl]phenyl ester, (3α,5β,7β)-
- NCX 1000